Gilead Sciences presented at the Baird Global Healthcare Conference 2025, outlining strategic advancements in its cell therapy subsidiary, Kite, including promising pipeline developments and expansion efforts, even as its flagship cell therapy products, Yescarta and Tecartus, faced competitive pressures and sales declines in the second quarter of 2025.

Gilead Sciences, Inc. (NASDAQ:GILD) showcased its strategic vision for its cell therapy franchise, Kite, at the Baird Global Healthcare Conference 2025. The presentation emphasized Kite's robust pipeline, including significant advancements in oncology and autoimmune indications, alongside initiatives to expand market access and enhance manufacturing efficiency. This strategic outlook comes as Gilead navigates a complex commercial landscape marked by competitive headwinds for its established cell therapy products.

Kite's Strategic Advancements and Pipeline Progress

At the forefront of Gilead's presentation were the ambitious goals for Kite. The subsidiary is actively working to broaden the accessibility of cell therapies beyond academic centers, streamline manufacturing processes, and develop next-generation treatments. A significant regulatory development highlighted was the FDA's removal of the REMS (Risk Evaluation and Mitigation Strategy) requirement for CD19-directed autologous CAR T therapies, which is anticipated to reduce burdens on healthcare providers and patients, potentially accelerating wider adoption.

Key pipeline programs underscore Kite's expansion. The AnitoCell program, targeting the fourth-line multiple myeloma market, is on track for a potential launch in 2026. Furthermore, Kite is enhancing its in vivo CAR T capabilities through the acquisition of Interius BioTherapeutics for $350 million. This acquisition aims to integrate Interius's innovative platform, enabling the generation of CAR T-cells directly within patients. Diversifying its therapeutic scope, Kite is also advancing studies in autoimmune and neurology indications, including lupus and multiple sclerosis, and exploring the solid tumor space with an initial focus on glioblastoma multiforme.

Commercial Performance and Financial Overview

While the strategic outlook for Kite is robust, Gilead's second-quarter 2025 financial results revealed mixed commercial performance for its cell therapy products. Total cell therapy product sales decreased by 7% year-over-year to $485 million. Sales of Yescarta (axicabtagene ciloleucel), a key cell therapy, saw a 5% decline to $393 million, primarily due to lower demand, though partially offset by higher average realized prices. Similarly, Tecartus experienced a 14% drop-off in sales to $92 million. Analysts at Leerink Partners commented,